Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM

Key Points

• Engineers Gate Manager LP more than doubled its Cullinan Therapeutics stake in the second quarter, increasing holdings by 130.9% to 153,050 shares. Institutional investors collectively own 86.31% of the company.
• Analyst sentiment remains broadly positive, with one Strong Buy, six Buy, one Hold and one Sell rating; the average price target is $33 versus the referenced share price of $20.40.
• Cullinan’s REZILIENT3 Phase 3 trial showed a six-month progression-free-survival benefit for zipalertinib plus chemotherapy, though shares initially fell about 6.3%, indicating investors viewed the results cautiously.

Engineers Gate Manager LP raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 130.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,050 shares of the company's stock after purchasing an additional 86,762 shares during the quarter. Engineers Gate Manager LP owned 0.24% of Cullinan Therapeutics worth $2,787,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Cullinan Therapeutics in the 2nd quarter worth $95,289,000. Blue Owl Capital Holdings LP bought a new stake in shares of Cullinan Therapeutics during the 2nd quarter worth $28,039,000. California State Teachers Retirement System lifted its holdings in shares of Cullinan Therapeutics by 2,311.4% during the 2nd quarter. California State Teachers Retirement System now owns 733,007 shares of the company's stock worth $13,348,000 after acquiring an additional 702,610 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Cullinan Therapeutics by 6.7% in the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company's stock worth $12,870,000 after acquiring an additional 57,259 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new position in Cullinan Therapeutics in the second quarter worth $12,828,000. Hedge funds and other institutional investors own 86.31% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. TD Cowen raised Cullinan Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. BTIG Research lifted their price target on Cullinan Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Monday. Wall Street Zen cut Cullinan Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. Wedbush increased their price objective on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a report on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cullinan Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $33.00.

Insider Transactions at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total transaction of $172,560.00. Following the transaction, the insider directly owned 158,844 shares of the company's stock, valued at approximately $3,426,265.08. This trade represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 46,000 shares of company stock worth $922,920 in the last ninety days. Corporate insiders own 8.60% of the company's stock.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG raised its price target to $40 and reaffirmed a Buy rating. The new target implies approximately 96% upside from the referenced $20.40 price, signaling that the analyst believes the REZILIENT3 data and Cullinan’s broader pipeline remain undervalued. BTIG price-target report
• Positive Sentiment: REZILIENT3 delivered a six-month median progression-free-survival benefit. Zipalertinib combined with chemotherapy outperformed chemotherapy alone in first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancer, providing potentially important support for the drug’s regulatory and commercial prospects. REZILIENT3 Phase 3 results
• Neutral Sentiment: Cullinan held a virtual analyst and investor event to discuss the interim REZILIENT3 analysis presented at the IASLC 2026 World Conference on Lung Cancer. The event gives management an opportunity to explain the data, address investor concerns and outline next steps, but the announcement itself did not add new clinical results. Cullinan investor event announcement
• Negative Sentiment: The initial market response to the Phase 3 results was negative. Reports indicated that CGEM shares fell about 6.3% after the announcement, suggesting investors may have viewed the data as insufficiently compelling relative to expectations despite the six-month PFS improvement. The company’s analyst call and additional disclosures may be important for determining whether the result represents a durable catalyst. CGEM shares fall after trial results

Cullinan Therapeutics Stock Performance

Shares of Cullinan Therapeutics stock opened at $20.40 on Tuesday. Cullinan Therapeutics, Inc. has a 52-week low of $5.68 and a 52-week high of $23.19. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -6.58 and a beta of 0.02. The company has a fifty day moving average of $19.51 and a 200-day moving average of $16.47.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.01). On average, equities research analysts forecast that Cullinan Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Cullinan Therapeutics Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company's approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.